Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WHR1 | P49842 | 7/20 | 0.67 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.59 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | CCR4 | P51679 | 2/20 | 0.54 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.53 |
| ▸ | KMT5A | Q9NQR1 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3639996 | 0.99 | WHR1 (0.66) | WHR1EHMT2EHMT1HRH4EGFR | |
| SCHEMBL3779862 | 0.89 | EHMT2 (0.68) | EHMT2HRH4EGFRCCR4KMT5A | |
| Hydrochloric Acid SCHEMBL3637894 | 0.88 | EHMT2 (0.67) | EHMT2HRH4EGFRCCR4KMT5A | |
| SCHEMBL3644755 | 0.86 | HRH4 (0.55) | HRH4 | |
| SCHEMBL3638792 | 0.81 | CTNNB1 (0.62) | HRH4 | |
| SCHEMBL25231380 | 0.81 | EHMT2 (0.70) | EHMT2EHMT1EZH2KMT5A | |
| SCHEMBL22144607 | 0.81 | EHMT2 (0.70) | WHR1EHMT2EHMT1EZH2KMT5A | |
| SCHEMBL25234583 | 0.81 | EHMT2 (0.69) | EHMT2EHMT1EZH2KMT5A | |
| SCHEMBL22144630 | 0.80 | WHR1 (1.00) | WHR1EHMT2EHMT1KMT5A | |
| SCHEMBL22144612 | 0.80 | WHR1 (0.85) | WHR1EHMT2EHMT1HRH4CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | claimed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | claimed |
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | disclosed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | TPX2, DCXR, RRM2 | WHR1 3571/4885EHMT2 3769/4885EHMT1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.